Smartphone app for detecting skin cancer
Clinical Performance and Patient Experience of an Artificial Intelligence-based Smartphone Application (Skinvision ®) in the Early Detection of Skin Cancer: A Cross-Sectional Study in a Real-life Setting.
This study tests whether the Skinvision App® can help people identify concerning skin lesions that might be skin cancer and need a doctor's attention.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 2500 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital, Ghent Academic / other |
| Locations | 1 site (Ghent, East Flanders) |
| Trial ID | NCT05246163 on ClinicalTrials.gov |
What this trial studies
This project aims to evaluate the effectiveness of the Skinvision App® in preselecting skin lesions that may indicate skin cancer and require urgent medical attention. Given the rising incidence of skin cancer, early detection is crucial for improving patient outcomes and reducing healthcare costs. The app uses algorithms to assess skin lesions, potentially enhancing the efficiency of skin cancer screening in the general population. The study will focus on individuals with specific concerning skin lesions to determine the app's accuracy in identifying those needing further evaluation.
Who should consider this trial
Good fit: Ideal candidates include adults over 18 with one or two concerning skin lesions that meet specific criteria.
Not a fit: Patients without any concerning skin lesions or those unable to provide informed consent may not benefit from this study.
Why it matters
Potential benefit: If successful, this app could significantly improve early detection of skin cancer, leading to better patient outcomes.
How similar studies have performed: Previous studies have shown promising results with similar approaches, indicating a potential for success in this novel application.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with one or two lesions meeting at least one of the following criteria: * New mole in an adult (\> 18 years old); * 'Ugly duckling' sign (i.e. mole that looks different from other moles in the same person) * Changing mole (size, color, shape or structure); * Rapid growing lesion * Non-healing lesion * Written informed consent of the patient Exclusion Criteria: * Lack of informed consent for study participation
Where this trial is running
Ghent, East Flanders
- Department of Dermatology, Ghent University Hospital — Ghent, East Flanders, Belgium (Recruiting)
Study contacts
- Principal investigator: Lieve Brochez, MD, PhD — Ghent University Hospital, Department of Dermatology
- Study coordinator: Julie Kips, MD
- Email: julie.kips@ugent.be
- Phone: +32487519041
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.